Press Releases

Jan 07, 2021
BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference    read more...
Dec 27, 2020
BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)    read more...
Dec 07, 2020
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)    read more...
Dec 07, 2020
BeiGene Presents Clinical Data on BRUKINSA® (Zanubrutinib) in B-Cell Malignancies and Waldenström’s Macroglobulinemia at the 62nd ASH Annual Meeting    read more...
Dec 06, 2020
BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting    read more...
Dec 01, 2020
BeiGene Announces Pricing of Public Offering by Selling Shareholders    read more...
Dec 01, 2020
BeiGene Launches Proposed Public Offering by Selling Shareholders    read more...
Nov 23, 2020
BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference    read more...
Nov 19, 2020
BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma    read more...
Nov 17, 2020
BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis    read more...
Nov 10, 2020
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China    read more...
Nov 05, 2020
BeiGene Reports Third Quarter 2020 Financial Results    read more...
Nov 05, 2020
BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting    read more...
Oct 06, 2020
BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071    read more...
Sep 17, 2020
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer    read more...
Sep 10, 2020
BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference    read more...
Sep 09, 2020
BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia    read more...
Sep 04, 2020
BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs    read more...
Aug 27, 2020
BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals    read more...
Aug 25, 2020
BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors    read more...